Semler Scientific, Inc. (SMLR)

NASDAQ: SMLR · IEX Real-Time Price · USD
29.21
+0.66 (2.31%)
Mar 28, 2024, 4:00 PM EDT - Market closed

Company Description

Semler Scientific, Inc. provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States.

The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition.

It also offers Insulin Insights, a software program that is used by a healthcare provider to optimize outpatient insulin dosing.

The company's products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, family practitioners, healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups and retailers.

It offers its products through sales representatives and distributors. The company was incorporated in 2007 and is headquartered in Santa Clara, California.

Semler Scientific, Inc.
Semler Scientific logo
Country United States
Founded 2007
IPO Date Feb 21, 2014
Industry Medical Devices
Sector Healthcare
Employees 92
CEO Dr. Douglas Murphy-Chutorian M.D.

Contact Details

Address:
2340-2348 Walsh Avenue, Suite 2344
Santa Clara, California 95051
United States
Phone 408-627-4557
Website semlerscientific.com

Stock Details

Ticker Symbol SMLR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001554859
CUSIP Number 81684M104
ISIN Number US81684M1045
Employer ID 26-1367393
SIC Code 3845

Key Executives

Name Position
Renae Cormier Chief Financial Officer, Principal Accounting Officer, Head of Corporate Communications and Business Strategy and Secretary
Dr. Douglas Murphy-Chutorian M.D. Chief Executive Officer, President and Director
Dr. Herbert J. Semler Founder and Chairman Emeritus
Jennifer Oliva Herrington Chief Operating Officer
Shane Reid Chief Technology Officer
Cindy Guinasso Senior Vice President of Business Development

Latest SEC Filings

Date Type Title
Mar 7, 2024 10-K Annual Report
Mar 5, 2024 8-K Current Report
Feb 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 26, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 22, 2024 8-K Current Report
Nov 13, 2023 10-Q Quarterly Report
Nov 9, 2023 8-K Current Report
Oct 23, 2023 8-K Current Report
Sep 14, 2023 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Sep 8, 2023 ARS Filing